Financial Services

Cohere Health's new Policy Studio uses AI to digitize archaic medical policies, promising to cut costs, ease provider burden, and meet new regulations.

HPP's routine preferred stock payout seems minor, but it reveals a deeper story of financial health and a strategic bet on a tech and media rebound.

With its 2026 Investor Day nearing, PHINIA aims to prove its dual-path strategy is the key to powering a diverse, carbon-conscious industrial future.

An Austin firm’s massive growth to $30B AUM reveals a key trend: specialized asset managers are becoming the new architects of our connected future.

Angeion Group's appointment of a legal marketing veteran isn't just a new hire; it's a calculated move to challenge rivals and dominate its niche.

A new military satellite project in the Arctic is about more than defence. It's a test for a new procurement model and a major bet on Canadian tech.

A family-owned store's record safe sales reveal a story of niche retail, tax incentives, and a parent company's ambitious 'patriotic lifestyle' gamble.

A famed NYC pub's arrival signals a new era for Atlanta's downtown, as the massive Centennial Yards project races to redefine the city for a global stage.

A massive silver discovery in Nevada isn't just a win for one company; it's a strategic move to secure America's tech and energy future. Here's why.

A new narcolepsy drug could finally offer patients what they've been missing: a single nightly dose with low sodium, transforming lives and the market.

Celldex is launching a pivotal Phase 3 trial for a drug that could be the first advanced therapy for two debilitating and untreated chronic hive conditions.

A top FinTech firm's new product chief reveals a strategic roadmap for taming complexity that the defense and space sectors cannot afford to ignore.

As AI systems grow more powerful, they also become vulnerable. A new German research initiative aims to build the tools to detect AI manipulation.

Wealth Enhancement's $2.2B deal for L.M. Kohn isn't just another acquisition. It signals a tech-fueled consolidation wave reshaping financial advice.

Eli Lilly's groundbreaking leukemia drug data signals a major market shift, promising better patient outcomes and fortifying its long-term growth strategy.

AskBio's gene therapies for Parkinson's and heart failure have received Japan's SAKIGAKE designation, promising a faster path to patients.

Accenture is training 30,000 pros on Anthropic's Claude AI, tackling the biggest barrier to enterprise AI: moving from costly experiments to real value.

Target RWE's strategic hire of NoviSci co-founder Alan Brookhart signals a major push to master regulatory-grade real-world evidence. What does this mean?

A new patent for its lead cancer drug in Japan is more than a legal win; it's a strategic move to secure a future market into the 2040s.

Spectral Capital projects massive growth via acquisitions and quantum tech, but its ambitious NASDAQ plan faces significant financial and execution hurdles.